These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2111623)

  • 1. [The outer membrane proteins of Neisseria meningitidis: the outlook for their use in developing preparations for immunoprophylaxis].
    Filatova TN
    Zh Mikrobiol Epidemiol Immunobiol; 1990 Feb; (2):86-95. PubMed ID: 2111623
    [No Abstract]   [Full Text] [Related]  

  • 2. [The outlook for the development of a vesicular meningococcal serogroup B vaccine].
    Del'vig AA; Semenov BF
    Zh Mikrobiol Epidemiol Immunobiol; 1998; (1):91-6. PubMed ID: 9532701
    [No Abstract]   [Full Text] [Related]  

  • 3. Status of a group B Neisseria meningitidis vaccine.
    Frasch CE
    Eur J Clin Microbiol; 1985 Dec; 4(6):533-6. PubMed ID: 3937731
    [No Abstract]   [Full Text] [Related]  

  • 4. Neisseria meningitidis: vaccines and vaccine candidates.
    Al'Aldeen AA; Cartwright KA
    J Infect; 1996 Nov; 33(3):153-7. PubMed ID: 8945702
    [No Abstract]   [Full Text] [Related]  

  • 5. [Vaccines against Neisseria meningitidis].
    Ferrón L; Criado MT; Ferreirós CM
    Enferm Infecc Microbiol Clin; 1992 May; 10(5):296-301. PubMed ID: 1391002
    [No Abstract]   [Full Text] [Related]  

  • 6. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
    Jennings HJ
    Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499
    [No Abstract]   [Full Text] [Related]  

  • 7. Vaccines for prevention of meningococcal disease.
    Frasch CE
    Clin Microbiol Rev; 1989 Apr; 2 Suppl(Suppl):S134-8. PubMed ID: 2497956
    [No Abstract]   [Full Text] [Related]  

  • 8. Meningococcal meningitis.
    Lancet; 1989 Mar; 1(8639):647-8. PubMed ID: 2564462
    [No Abstract]   [Full Text] [Related]  

  • 9. Vaccines against meningococcal meningitis: current status.
    Epidemiol Bull; 1994 Jul; 15(2):13-5. PubMed ID: 8086300
    [No Abstract]   [Full Text] [Related]  

  • 10. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine.
    Claassen I; Meylis J; van der Ley P; Peeters C; Brons H; Robert J; Borsboom D; van der Ark A; van Straaten I; Roholl P; Kuipers B; Poolman J
    Vaccine; 1996 Jul; 14(10):1001-8. PubMed ID: 8873395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacterial outer membrane protein vaccines. The meningococcal example.
    Poolman JT
    Adv Exp Med Biol; 1996; 397():73-7. PubMed ID: 8718585
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunopotentiating ability of neisserial major outer membrane proteins. Use as an adjuvant for poorly immunogenic substances and potential use in vaccines.
    Wetzler LM
    Ann N Y Acad Sci; 1994 Aug; 730():367-70. PubMed ID: 8080211
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.
    Noronha CP; Struchiner CJ; Halloran ME
    Int J Epidemiol; 1995 Oct; 24(5):1050-7. PubMed ID: 8557439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meningococcal vaccines--present and future.
    Zollinger WD; Moran E
    Trans R Soc Trop Med Hyg; 1991; 85 Suppl 1():37-43. PubMed ID: 1803695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies.
    Rosenqvist E; Høiby EA; Wedege E; Kusecek B; Achtman M
    J Infect Dis; 1993 May; 167(5):1065-73. PubMed ID: 8486938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bactericidal antibody response to Neisseria meningitidis serogroup B in patients with bacterial meningitis: effect of immunization with an outer membrane protein vaccine.
    Milagres LG; Gorla MC; Rebelo MC; Barroso DE
    FEMS Immunol Med Microbiol; 2000 Aug; 28(4):319-27. PubMed ID: 10891656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model: new prospects for vaccine development.
    Saukkonen K; Abdillahi H; Poolman JT; Leinonen M
    Microb Pathog; 1987 Oct; 3(4):261-7. PubMed ID: 3143885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbiology. A furtive pathogen revealed.
    Nassif X
    Science; 2000 Mar; 287(5459):1767-8. PubMed ID: 10755929
    [No Abstract]   [Full Text] [Related]  

  • 19. Antibody studies in mice of outer membrane antigens for use in an improved meningococcal B and C vaccine.
    Milagres LG; Cristina M; Brandileone MC; Sacchi CT; Vieira VS; Zanella RC; Frasch CE
    FEMS Immunol Med Microbiol; 1996 Jan; 13(1):9-17. PubMed ID: 8821393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mouse model utilising human transferrin to study protection against Neisseria meningitidis serogroup B induced by outer membrane vesicle vaccination.
    Oftung F; Lovik M; Andersen SR; Froholm LO; Bjune G
    FEMS Immunol Med Microbiol; 1999 Oct; 26(1):75-82. PubMed ID: 10518045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.